Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multiple myeloma genetic discovery promises better treatment:

This article was originally published in Clinica

Executive Summary

US researchers have categorised four distinguishing gene patterns for the blood cancer multiple myeloma, which could allow doctors to better predict how patients will respond to current treatments. The team, which included collaborators from the Dana-Farber Cancer Institute in Boston, Massachusetts, said that patients with each gene pattern can be correlated with different clinical outcomes. The findings could lead to the design of drugs targeted at these specific gene patterns. The results appear in the April issue of Cancer Cell. Mutiple myeloma is the second most common form of blood cancer after non-Hodgkin's lymphoma.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel